Toggle navigation
COVID-19
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
SITC 2021
NCCN 2021 Virtual Congress: Hematologic Malignancies
2021 Lynn Sage Breast Cancer Symposium
2021 ASTRO Annual Meeting
AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Conquer Cancer Foundation
November 10, 2018
Advertisement
Advertisement
Advertisement
Dec
04
Today In Oncology
Eftilagimod Alpha Plus Paclitaxel May Improve Survival in HR-Positive, HER2-Negative Metastatic Breast Cancer AIPAC Trial
Study Examines Safety and Efficacy of Retifanlimab in Recurrent MSI-H/dMMR Endometrial Cancer
Sotigalimab Plus Nivolumab in Anti–PD-1/PD-L1–Refractory Melanoma
Vidutolimad Plus Pembrolizumab in PD-1 Refractory Melanoma
Novel Vaccine Platform Plus Pembrolizumab May Boost Immune Response in Advanced HCC
View More
Advertisement
